Elicera Therapeutics
3.13 SEK
0.00 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
0.00 %
-43.14 %
-34.57 %
-38.46 %
-40.62 %
-32.30 %
-8.74 %
-
-48.19 %
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
227.87M SEK
Turnover
239.35K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
21/8
2026
Interim report Q2'26
27/11
2026
Interim report Q3'26
16/2
2027
Annual report '26
All
Research
Press releases
3rd party
ShowingAll content types
Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO
Carlsquare: Analysuppdatering Elicera Therapeutics: Höjer insatserna efter framsteg
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools